scholarly journals Comparable Enhanced Prothrombogenesis in Simple Central Obesity and Metabolic Syndrome

2018 ◽  
Vol 2018 ◽  
pp. 1-6
Author(s):  
Noor Shafina Mohd Nor ◽  
Hanis Saimin ◽  
Thuhairah Rahman ◽  
Suraya Abdul Razak ◽  
Nadzimah Mohd Nasir ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Plasminogen Activator ◽  
Central Obesity ◽  
International Diabetes Federation ◽  
Plasminogen Activator Inhibitor ◽  
Cross Sectional Study ◽  
Blood Levels ◽  
Plasminogen Activator Inhibitor 1 ◽  
Cross Sectional ◽  
Pai 1

Objective. There is limited data comparing prothrombogenic or fibrinolysis biomarkers (tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1)) simultaneously in subjects with Metabolic Syndrome (MS), simple central obesity without MS (COB) and normal controls (NC). We investigated the concentrations of fibrinolysis biomarkers in subjects with MS, COB and NC.Methods. A cross-sectional study involving 503 drug naive subjects (163 males, aged 30–65 years old (mean age ± SD = 47.4 ± 8.3 years)) divided into MS, COB and NC groups. COB was defined as central obesity (waist circumference (WC) males ≥90 cm, females ≥80 cm) in the absence of MS according to the International Diabetes Federation 2006. Fasting blood levels of tPA and PAI-1were analyzed.Results. MS and COB had significantly higher concentration of all biomarkers compared to NC. The MS group had significantly higher concentration of tPA and PAI-1 compared to COB. WC and HDL-c had significant correlation with all biomarkers (tPAp<0.001, PAI-1p<0.001). Fasting plasma glucose and diastolic blood pressure were independent predictors after correcting for confounding factors.Conclusion. Central obesity with or without MS both demonstrated enhanced prothrombogenesis. This suggests that simple obesity possibly increases the risk of coronary artery disease in part, via increased susceptibility to thrombogenesis.

scholarly journals Correlation between Inflammation and Fibrinolysis in Hypertensive Centrally Obese Subjects: A Study on C-Reactive Protein, Plasminogen Activator Inhibitor-1 and Thrombin Activatable Fibrinolysis Inhibitor

2012 ◽  
Vol 4 (3) ◽  
pp. 151
Author(s):  
Yati Sumiyati ◽  
Syakib Bakri ◽  
Mansyur Arif
Keyword(s):  
Central Obesity ◽  
Vascular Inflammation ◽  
Plasminogen Activator Inhibitor ◽  
Cross Sectional Study ◽  
Plasminogen Activator Inhibitor 1 ◽  
Cross Sectional ◽  
Disease Epidemiology ◽  
Obese Subjects ◽  
Hs Crp ◽  
Pai 1

BACKGROUND: Hypertension and central obesity are risk factors of cardiovascular disease. Epidemiology studies have shown that these two conditions are closely linked and often occur simultaneously. Inflammation is an underlying pathomechanism in hypertension and obesity. Vascular inflammation is related to coagulation pathway, whereby high level of inflammation increases the risk of atherothrombosis event. The aim of this study was to investigate the correlation between inflammation and fibrinolysis in hypertensive centrally obese subjects compared with hypertensive non obese sbjects.METHODS: This was a cross sectional study conducted in October 2009-June 2010 involving 53 eligible subjects according to the following criteria: men or women aged 30-65 years, had neither diabetes (FPG <126 mg/dL and or OGTT <200 mg/dL) nor CKD (eGFR ≥60 mL/minutes). All subjects were not in an acute inflammation state, had no unspecific infection (hs-CRP ≤10 mg/L), or taking anti-inflammation or anti-hypertensive medication.RESULTS: In this study we found that the levels of hs-CRP (2.636 mg/L vs 1.024 mg/L, p=0.007), PAI-1 (43.58 ng/mL vs. 28.43 ng/mL, p=0.089) and TAFI (12.73 ng/mL vs. 12.19 ng/mL, p=0.479) were respectively higher in hypertensive subjects with central obesity than in hypertensive subjects with no central obesity. In hypertensive centrally obese subjects there was significant positive correlation between hs-CRP and PAI-1 (r=0.491, p=0.001) and TAFI (r=0.312, p=0.0390, meanwhile in hypertensive non-obese subjects significant correlation was found only between hs-CRP and TAFI (r=0.929, p=0.003).CONCLUSIONS: Obesity in hypertensive subjects has higher inflammation state that is correlated with fibrinolysis disruption.KEYWORDS: hypertensive, obesity, hs-CRP, PAI-1, TAFI

scholarly journals Association among Fibrinolytic Proteins, Metabolic Syndrome Components, Insulin Secretion, and Resistance in Schoolchildren

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Jin-Shuen Chen ◽  
Chung-Ze Wu ◽  
Nain-Feng Chu ◽  
Li-Chien Chang ◽  
Dee Pei ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Insulin Secretion ◽  
Plasminogen Activator ◽  
High Sensitivity ◽  
Plasminogen Activator Inhibitor ◽  
Normal Group ◽  
Plasminogen Activator Inhibitor 1 ◽  
Reactive Protein ◽  
Fibrinolytic Proteins ◽  
Pai 1

We investigated the role of urokinase plasminogen activator (uPA) and its soluble receptors (suPAR) and plasminogen activator inhibitor-1 (PAI-1) in metabolic syndrome (MetS) components, insulin secretion, and resistance in schoolchildren. We enrolled 387 children, aged 10.3 ± 1.5 years, in Taipei. Anthropometry, fibrinolytic proteins, MetS components, insulin secretion, and resistance were measured. Subjects were divided into normal, overweight, and obese groups. Finally, the relationship between fibrinolytic proteins and metabolic syndrome in boys and girls was analyzed. In boys, PAI-1 was positively associated with body mass index (BMI) percentile, hypertriglyceride, insulin secretion, and resistance. In girls, PAI-1 was positively associated with obesity, hypertriglyceridemia, and insulin secretion. In girls, uPA was positively associated with insulin secretion. suPAR was positively associated with high-sensitivity C-reactive protein in both boys and girls, and with BMI percentile and body fat in girls. The obese boys had higher suPAR and PAI-1 levels than the normal group. The obese girls had higher uPA, suPAR, and PAI-1 than the normal group. Boys and girls with MetS had higher PAI-1. Fibrinolytic proteins, especially PAI-1, are associated with MetS components and insulin secretion in children. Fibrinolytic proteins changes were more likely to occur in girls than in boys.

scholarly journals Prevalence of Metabolic Syndrome and Its Components in Adults with Central Obesity at Janakpur Zone, Nepal

2021 ◽  
Vol 18 (4) ◽  
pp. 681-685
Author(s):  
Birendra Kumar Jha ◽  
Mingma Lhamu Sherpa ◽  
Binod Kumar Dahal ◽  
Jitendra Kumar Singh
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Central Obesity ◽  
International Diabetes Federation ◽  
Cross Sectional Study ◽  
High Density Lipoproteins ◽  
Cluster Sampling ◽  
Cross Sectional ◽  
The Metabolic Syndrome

Background: Urbanization, surplus energy uptake, decreased physical activities are general risk factors of metabolic syndrome However, it’s status, and associated components remain unexplored in the Terai region of Nepal. This study evaluated the prevalence of metabolic syndrome and its components among adults with central obesity of Terai region of Nepal using International Diabetes Federation criteria.Methods: Community based cross-sectional study was conducted in three Terai districts of Janakpur Zone, Nepal. A total of 378 adults having central obesity were selected using cluster sampling by camp approach. Interview, physical and clinical examination, measurement of fasting blood sugar, and lipid profile were conducted for all participants. The prevalence of metabolic syndrome and its components with 95% CI were estimated.Results: The metabolic syndrome prevalence was 74.9% (95% CI:70.2-79.2%), with no significant differences between male (77.7%, 95% CI:71.0-83.5%) and female (72.2%, 95% CI: 65.2-78.3%). The most common factors observed were low high density lipoproteins with highly significant differences between male (77.7%, 95% CI:71.0-83.5%)) and female (90.2%, 95% CI: 85.094.0%-; p=0.001) and hypertriglyceridemia with significant differences between male (57.6%, 95% CI: 50.1-64.5%) and female (46.9%, 95% CI: 39.7-54.2%; p=0.037). Conclusions: Higher prevalence of metabolic syndrome and its risk factors in Janakpur of Nepal likely suggest lack of awareness and health promotion activities for metabolic syndrome and indicate an urgency for a public health program to maintain quality of life. Keywords: Metabolic syndrome; Nepal; prevalence; risk factors; terai

scholarly journals Assessment of plasminogen activator inhibitor-1 in obese Egyptian children

2020 ◽  
Vol 68 (1) ◽  
Author(s):  
Marwa Farouk Mira ◽  
Ghada Mohammad Anwar ◽  
Azza Mohamed Sarry EL-Din ◽  
Safinaz Mohammed Megahed
Keyword(s):  
Metabolic Syndrome ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Anthropometric Measurements ◽  
Obese Children ◽  
Plasminogen Activator Inhibitor 1 ◽  
Skin Fold Thickness ◽  
Skin Fold ◽  
Activator Inhibitor ◽  
Pai 1

Abstract Background Plasminogen activator inhibitor-1 (PAI-1) is mainly produced in the liver and in the adipose tissue. Normal fibrin clearance mechanisms were found to be affected by high plasma PAI-1 levels and thus increases risk of thrombosis. The aim of the current study was to expound the childhood obesity effect on circulating PAI-1 and interpret the relation of PAI-1 to metabolic syndrome. This cross-sectional study was conducted on 43 obese children following in the Children Hospital and compared to 44 healthy sex- and age-matched controls. All recruited cohort are subjected to anthropometric measurements: weight, height, BMI, waist circumference, hip circumference, and skin fold thickness (biceps, triceps, and subscapular), and laboratory investigations in the form of lipid profile, fasting blood sugar, fasting insulin, insulin resistance estimated by HOMA-IR, and plasminogen activator inhibitor-1. Results The level of plasminogen activator inhibitor-1 in the obese group was significantly higher than that in the control group (47.98 ± 17.42 vs. 28.00 ± 11.35 respectively). PAI-1 showed positive significant correlation to anthropometric measurements: BMI (p = 0.000), weight (p = 0.000), biceps skin fold thickness (p = 0.04), triceps skin fold thickness (p = 0.4), and subscapular skin fold thickness (p = 0.04). Also, a significant positive correlation was found between PAI-1 and systolic (p = 0.000) and diastolic blood pressure (p = 0.04). Positive correlations were found between PAI-1 and cholesterol (p = 0.000), triglycerides (p = 0.02), LDL-c (p = 0.000), insulin (p = 0.000), and HOMA-IR (r = 0.5, p = 0.02). Conclusion Fat mass accumulation is related to high PAI-1 levels, which might in turn contribute to cardiovascular risk. Plasminogen Activator Inhibitor-1 is a good predictive test for metabolic syndrome in obese children.

scholarly journals The Role of Plasminogen Activator Inhibitor-1 in the Metabolic Syndrome and Its Regulation

2014 ◽  
Vol 3 (6) ◽  
pp. 36 ◽  
Author(s):  
Martha Phelan ◽  
David M. Kerins
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
The Metabolic Syndrome ◽  
Activator Inhibitor ◽  
Pai 1

<p>Obesity is a major risk factor for cardiovascular disease (CVD). Lipid abnormalities, hypertension, impaired glucose tolerance or diabetes, are cardiovascular risk factors that are frequently present in patients with obesity. Haemostatic and fibrinolytic disturbances are also considered to be important risk factors for CVD hence, a potential link between CVD, obesity and the metabolic syndrome arises. Regulation of the fibrinolytic system can occur at the level of plasminogen activators and plasminogen activator inhibitor-1 (PAI-1). PAI-1, a glycoprotein, is one of the most important inhibitors of fibrinolysis. Regulation of this serine protease inhibitor may have a beneficial effect on other conditions associated with the metabolic syndrome. Human adipose tissue is a source of PAI-1. PAI-1 production may in turn be controlled by a number of hormones and cytokines which are secreted by adipose tissue in addition to dietary factors. In this review we summarise the current knowledge regarding the role of altered fibrinolytic function in obesity, CVD and hence the metabolic syndrome. Regulatory factors including different dietary components, weight loss and dietary intervention will also be discussed.</p>

The study of markers of endothelial dysfunction in metabolic syndrome

2015 ◽  
Vol 24 (3) ◽  
Author(s):  
Ashok Kumar Ahirwar ◽  
Anju Jain ◽  
Archana Singh ◽  
Binita Goswami ◽  
M.K. Bhatnagar ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Endothelial Dysfunction ◽  
Serum Insulin ◽  
International Diabetes Federation ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
Increased Risk ◽  
The Difference ◽  
Pai 1

AbstractMetabolic syndrome (MetS) consists of a constellation of metabolic abnormalities that confer increased risk of cardiovascular disease (CVD) and diabetes mellitus (DM). Endothelial dysfunction is one of the key components of MetS which is caused by imbalance between vasodilatory substances like nitric oxide (NO) and vaso-constrictive substances like endothelin and prothrombotic factors like plasminogen activator inhibitor-1 (PAI-1).To study the markers of endothelial dysfunction (NO and endothelin) and prothrombotic markers (PAI-1) among the study subjects.We enrolled 50 diagnosed cases of MetS as per International Diabetes Federation (IDF) criteria and 50 healthy volunteers as controls. Clinical evaluation included anthropometric, routine biochemical, hematological, serum insulin, NO, endothelin and PAI-1 measurements.Subjects with MetS had higher insulin, endothelin and PAI-1 levels and low NO levels as compared to controls and the difference was found to be significant. The serum insulin levels were positively correlated with PAI-1 and endothelin, and negatively correlated with NO.Endothelial functional status as reflected by decreased NO and increased serum endothelin levels along with insulin resistance is seen in MetS. Moreover, higher serum level of PAI-1 also tilts towards a more prothrombotic milieu in the vascular endothelium. Hence endothelial dysfunction and prothrombotic markers may be used to guide for early diagnosis of cardiovascular disease and type 2 diabetes in patients with MetS.

scholarly journals Significant inverse associations of serumn-6 fatty acids with plasma plasminogen activator inhibitor-1

2011 ◽  
Vol 107 (4) ◽  
pp. 567-572 ◽  
Author(s):  
Sunghee Lee ◽  
J. David Curb ◽  
Takashi Kadowaki ◽  
Rhobert W. Evans ◽  
Katsuyuki Miura ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Capillary Liquid Chromatography ◽  
Free Form ◽  
Japanese American ◽  
Plasminogen Activator Inhibitor 1 ◽  
Cross Sectional ◽  
Activator Inhibitor ◽  
Pai 1

Epidemiological studies suggested thatn-6 fatty acids, especially linoleic acid (LA), have beneficial effects on CHD, whereas somein vitrostudies have suggested thatn-6 fatty acids, specifically arachidonic acid (AA), may have harmful effects. We examined the association of serumn-6 fatty acids with plasminogen activator inhibitor-1 (PAI-1). A population-based cross-sectional study recruited 926 randomly selected men aged 40–49 years without CVD during 2002–2006 (310 Caucasian, 313 Japanese and 303 Japanese-American men). Plasma PAI-1 was analysed in free form, both active and latent. Serum fatty acids were measured with gas-capillary liquid chromatography. To examine the association between totaln-6 fatty acids (including LA and AA) and PAI-1, multivariate regression models were used. After adjusting for confounders, totaln-6 fatty acids, LA and AA, were inversely and significantly associated with PAI-1 levels. These associations were consistent across three populations. Among 915 middle-aged men, serumn-6 fatty acids had significant inverse associations with PAI-1.

scholarly journals Association of dietary patterns and practices on metabolic syndrome in adults with central obesity attending a mission hospital in Kenya: a cross-sectional study

BMJ Open ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. e039131
Author(s):  
Okubatsion Tekeste Okube ◽  
Samuel Kimani ◽  
Mirie Waithira
Keyword(s):  
Metabolic Syndrome ◽  
Dietary Patterns ◽  
Central Obesity ◽  
International Diabetes Federation ◽  
Time Lapse ◽  
Cross Sectional Study ◽  
Dietary Behaviour ◽  
Cross Sectional ◽  
Fast Foods ◽  
Mission Hospital

ObjectiveDietary patterns and practices can predispose or protect against metabolic syndrome (MetS) in humans. Despite the growing problem of MetS in adults, the underpinning dietary behaviour is poorly understood. We determined the dietary patterns and practices relevant to MetS in adults with central obesity attending a mission hospital in Kenya.Study designDescriptive, cross-sectional.SettingOutpatient clinic of a mission-based hospital in Nairobi.ParticipantsAdults (N=404) aged 18–64 years diagnosed with central obesity as per the International Diabetes Federation definition for MetS.Primary outcomesAnthropometric measurements, clinical-biochemical markers and dietary components, quantity and frequency of food intake, as well as time-lapse between consumption of dinner and sleeping.ResultsA high (87.2%) prevalence of MetS was observed for respondents who reported consumption of large amount of carbohydrates (p<0.001), proteins (p<0.001), processed/fast foods (p<0.001) and sugar (p=0.009). Frequent consumption of legumes (p<0.001), nuts (p<0.001), fruits (p<0.001) and vegetables (p=0.021) was linked to reduced MetS. Additionally, longer interval between eating dinner and going to bed was associated with reduced MetS.ConclusionRegular consumption of fruits, vegetables, legumes and nuts, as well as observing sometime after eating dinner before sleeping, was the dietary pattern significantly associated with a lower risk of MetS. Whereas, consumption of a large quantity of carbohydrates, proteins, processed/fast foods and sugar is likely to predispose to MetS. The findings underscore the need to focus on specific dietary intake patterns including frequency, quantity, quality and variety for MetS prevention and management. The MetS-related interventions could be implemented during individual consultation, group and community health messaging sessions.

scholarly journals A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease

2021 ◽  
Vol 8 ◽  
Author(s):  
Gael B. Morrow ◽  
Claire S. Whyte ◽  
Nicola J. Mutch
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
Central Function ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Thrombotic Complications ◽  
Pai 1

Plasminogen activator inhibitor 1 (PAI-1) is a member of the serine protease inhibitor (serpin) superfamily. PAI-1 is the principal inhibitor of the plasminogen activators, tissue plasminogen activator (tPA), and urokinase-type plasminogen activator (uPA). Turbulence in the levels of PAI-1 tilts the balance of the hemostatic system resulting in bleeding or thrombotic complications. Not surprisingly, there is strong evidence that documents the role of PAI-1 in cardiovascular disease. The more recent uncovering of the coalition between the hemostatic and inflammatory pathways has exposed a distinct role for PAI-1. The storm of proinflammatory cytokines liberated during inflammation, including IL-6 and TNF-α, directly influence PAI-1 synthesis and increase circulating levels of this serpin. Consequently, elevated levels of PAI-1 are commonplace during infection and are frequently associated with a hypofibrinolytic state and thrombotic complications. Elevated PAI-1 levels are also a feature of metabolic syndrome, which is defined by a cluster of abnormalities including obesity, type 2 diabetes, hypertension, and elevated triglyceride. Metabolic syndrome is in itself defined as a proinflammatory state associated with elevated levels of cytokines. In addition, insulin has a direct impact on PAI-1 synthesis bridging these pathways. This review describes the key physiological functions of PAI-1 and how these become perturbed during disease processes. We focus on the direct relationship between PAI-1 and inflammation and the repercussion in terms of an ensuing hypofibrinolytic state and thromboembolic complications. Collectively, these observations strengthen the utility of PAI-1 as a viable drug target for the treatment of various diseases.

Sign in / Sign up

Export Citation Format

Share Document